Found: 7
Select item for more details and to access through your institution.
A status report on RNAi therapeutics.
- Published in:
- Silence, 2010, v. 1, n. 1, p. 1, doi. 10.1186/1758-907X-1-14
- By:
- Publication type:
- Article
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
- Published in:
- Cardiovascular Drugs & Therapy, 2020, v. 34, n. 3, p. 357, doi. 10.1007/s10557-019-06919-4
- By:
- Publication type:
- Article
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-31757-8
- By:
- Publication type:
- Article
Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-91113-6
- By:
- Publication type:
- Article
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.
- Published in:
- Toxicologic Pathology, 2018, v. 46, n. 7, p. 735, doi. 10.1177/0192623318792537
- By:
- Publication type:
- Article
Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 2, p. 372, doi. 10.1002/cpt.1974
- By:
- Publication type:
- Article